{
    "nctId": "NCT00657345",
    "briefTitle": "IRS Proteins and Trastuzumab Resistance",
    "officialTitle": "IRS Proteins and Trastuzumab Resistance",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 9,
    "primaryOutcomeMeasure": "A tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab to try to elucidate the mechanism of trastuzumab resistance in patients with HER2-positive breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women age 18-70 with breast cancer who have signed an IRB approved consent form.\n2. Biopsy proven breast cancer with her 2 overexpression by fluorescence in situ hybridization (FISH).\n3. Newly diagnosed patients with Stages 1,2 and 3 breast cancer who will be receiving neoadjuvant chemotherapy prior to breast surgery\n4. Normal Left ventricular ejection fraction, as measured by echocardiogram or MUGA scan\n5. Normal bone marrow, kidney and liver function\n6. No evidence of distant metastatic disease\n\nExclusion Criteria:\n\n1. Patients with significant cardiac disease including abnormal LVEF, symptomatic coronary artery disease, uncontrolled hypertension.\n2. Prior treatment with chemotherapy.\n3. Any cancer other than previously treated skin cancer.\n4. Breast cancer in a previously irradiated breast.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}